The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.
 
Caitlin McIntyre
No Relationships to Disclose
 
Vasilisa Rudneva
No Relationships to Disclose
 
Allison Richards
No Relationships to Disclose
 
Wungki Park
Honoraria - American Physician Institute; Curio Science; IntegrityCE
Consulting or Advisory Role - Astellas Pharma; Cerner Enviza; EXACT Therapeutics; Innovent Biologics; Regeneron
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Break Through Cancer (Inst); Merck (Inst); Miracogen (Inst); NIH (Inst); NIH (Inst); Parker Institute for Cancer Immunotherapy (Inst); Revolution Medicines (Inst); The Society of Memorial Sloan Kettering (Inst)
 
William Jarnagin
No Relationships to Disclose
 
Mark Donoghue
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Research Funding - Loxo
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma